{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:16:56Z","timestamp":1782926216031,"version":"3.54.5"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"am","delay-in-days":390,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K24DK101828"],"award-info":[{"award-number":["K24DK101828"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017245","name":"Hennepin Healthcare Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jcf.2025.01.006","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T07:46:22Z","timestamp":1737186382000},"page":"278-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Racial disparities in lung transplantation for cystic fibrosis in the era of highly effective modulator therapy"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5749-5505","authenticated-orcid":false,"given":"Jessica M.","family":"Ruck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7167-5000","authenticated-orcid":false,"given":"Shi Nan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0902-0422","authenticated-orcid":false,"given":"Alexandra H.","family":"Toporek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pali D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5968-8384","authenticated-orcid":false,"given":"Erin","family":"Tallarico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9088-8749","authenticated-orcid":false,"given":"Noah","family":"Lechtzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan B.","family":"Massie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorry L.","family":"Segev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1251-8467","authenticated-orcid":false,"given":"Errol L.","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9283-3928","authenticated-orcid":false,"given":"Christian A.","family":"Merlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jcf.2025.01.006_bib0001","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","article-title":"Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation","volume":"182","author":"Sanders","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcf.2025.01.006_bib0002","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s41030-021-00170-9","article-title":"CFTR modulator therapy and its impact on lung transplantation in cystic fibrosis","volume":"7","author":"Benden","year":"2021","journal-title":"Pulm Ther"},{"key":"10.1016\/j.jcf.2025.01.006_bib0003","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.pharmthera.2016.11.009","article-title":"New horizons for cystic fibrosis treatment","volume":"170","author":"Fajac","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jcf.2025.01.006_bib0004","unstructured":"2015-CFF-Patient-Registry-Annual-Data-Report.pdf [Internet]. [cited 2024 May 6]. Available from: https:\/\/www.cisztasfibrozis.hu\/wp-content\/files\/registry\/int\/CF%20Foundation%20-%20USA\/2015-CFF-Patient-Registry-Annual-Data-Report.pdf."},{"key":"10.1016\/j.jcf.2025.01.006_bib0005","unstructured":"NACFC 2020 | Plenary 2: defining the New CF in the era of highly effective modulators - YouTube [Internet]. [cited 2023 Dec 1]. Available from: https:\/\/www.youtube.com\/watch?v=qOIA7v2K0K8."},{"issue":"3","key":"10.1016\/j.jcf.2025.01.006_bib0006","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1513\/AnnalsATS.201707-539OT","article-title":"Cystic fibrosis foundation pulmonary guidelines. use of cystic fibrosis transmembrane conductance regulator modulator therapy in patients with cystic fibrosis","volume":"15","author":"Ren","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"9","key":"10.1016\/j.jcf.2025.01.006_bib0007","first-page":"e29359","article-title":"Newly discovered cutting-edge triple combination cystic fibrosis therapy: a systematic review","volume":"14","author":"Dawood","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.jcf.2025.01.006_bib0008","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s41030-020-00115-8","article-title":"Real-World outcomes among patients with cystic fibrosis treated with ivacaftor: 2012-2016 experience","volume":"6","author":"Higgins","year":"2020","journal-title":"Pulm Ther"},{"issue":"1","key":"10.1016\/j.jcf.2025.01.006_bib0009","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor\u2013tezacaftor\u2013ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcf.2025.01.006_bib0010","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"9","key":"10.1016\/j.jcf.2025.01.006_bib0011","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/17476348.2016.1196140","article-title":"Socioeconomic status and health outcomes: cystic fibrosis as a model","volume":"10","author":"Oates","year":"2016","journal-title":"Expert Rev Respir Med"},{"issue":"10","key":"10.1016\/j.jcf.2025.01.006_bib0012","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1164\/rccm.201205-0949OC","article-title":"Disparities in access to lung transplantation for patients with cystic fibrosis by socioeconomic status","volume":"186","author":"Quon","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.jcf.2025.01.006_bib0013","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ppul.10042","article-title":"Case-mix adjustment for evaluation of mortality in cystic fibrosis","volume":"33","author":"O'Connor","year":"2002","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.jcf.2025.01.006_bib0014","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1164\/rccm.201711-2357OC","article-title":"Disparities in mortality of hispanic patients with cystic fibrosis in the United States. a national and regional cohort study","volume":"198","author":"Rho","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 3","key":"10.1016\/j.jcf.2025.01.006_bib0015","first-page":"S74","article-title":"The demographics of adverse outcomes in cystic fibrosis","volume":"54","author":"McGarry","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.jcf.2025.01.006_bib0016","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.jcf.2025.01.006_bib0017","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/humu.10041","article-title":"Cystic fibrosis: a worldwide analysis of CFTR mutations\u2013correlation with incidence data and application to screening","volume":"19","author":"Bobadilla","year":"2002","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jcf.2025.01.006_bib0018","unstructured":"2021 Annual data report. 2021."},{"issue":"2","key":"10.1016\/j.jcf.2025.01.006_bib0019","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ppul.26209","article-title":"Detection of disease-causing CFTR variants in state newborn screening programs","volume":"58","author":"McGarry","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"10","key":"10.1016\/j.jcf.2025.01.006_bib0020","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1513\/AnnalsATS.201603-192BC","article-title":"Minorities are underrepresented in clinical trials of pharmaceutical agents for cystic fibrosis","volume":"13","author":"McGarry","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2025.01.006_bib0021","unstructured":"Theratyping | Cystic Fibrosis Foundation [Internet]. [cited 2023 Nov 9]. Available from: https:\/\/www.cff.org\/research-clinical-trials\/theratyping."},{"key":"10.1016\/j.jcf.2025.01.006_bib0022","unstructured":"Vespa J, Medina L, Armstrong DM. Population estimates and projections. 2020. Accessed Sept 1, 2024. https:\/\/www.census.gov\/content\/dam\/Census\/library\/publications\/2020\/demo\/p25-1144.pdf."},{"issue":"12","key":"10.1016\/j.jcf.2025.01.006_bib0023","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.2105\/AJPH.2015.302903","article-title":"Implicit racial\/ethnic bias among health care professionals and its influence on health care outcomes: a systematic review","volume":"105","author":"Hall","year":"2015","journal-title":"Am J Public Health"},{"key":"10.1016\/j.jcf.2025.01.006_bib0024","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12939-021-01616-x","article-title":"A scoping review of inequities in access to organ transplant in the United States","volume":"21","author":"Park","year":"2022","journal-title":"Int J Equity Health"},{"issue":"2","key":"10.1016\/j.jcf.2025.01.006_bib0025","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jcf.2015.11.005","article-title":"Predictors of non-referral of patients with cystic fibrosis for lung transplant evaluation in the United States","volume":"15","author":"Ramos","year":"2016","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:36:00Z","timestamp":1777332960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325000086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1569199325000086"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.01.006","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Racial disparities in lung transplantation for cystic fibrosis in the era of highly effective modulator therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}